[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574497":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Enrolled patients",null,"The final personalized management strategy is determined based on both current conventional treatment options and physicians' and patients' preferences. The following agents might be applied: proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, anti-CD38 monoclonal antibodies, bispecific antibodies, and cell therapy, with or without steroids.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Peng Liu, Ph.D","CONTACT","+862164041990 ext 2315","liu.peng@zs-hospital.sh.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Zhongshan Hospital, Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":36,"investigatorFullName":37,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Peng Liu","100574497","longitudinal-data-registry-of-plasma-cell-dyscrasia-100574497",false,"NCT06760052","Longitudinal Data Registry of Plasma Cell Dyscrasia","Longitudinal Data Registry of a Spectrum of Plasma Cell Dyscrasia with Long-term Follow-up","Inclusion Criteria:\n\nPatients with pathological diagnosis of PCD \\[e.g.: symptomatic\u002Fasymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), POEMS syndrome, light chain (AL) amyloidosis) from 2007 to 2027 in Zhonshan Hospital.\n\nPatients who had complete diagnostic, treatment and follow-up records. With fully comprehension and signature of the informed consent form (ICF) for participation.\n\nExclusion Criteria:\n\nPatients who refused to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.\n\nPatients who suffered from severe mental illness. Patients who were deemed unsuitable for inclusion by the investigator.","ALL","19 Years","99 Years",{"count":49,"type":50},2000,"ESTIMATED","OBSERVATIONAL","This study aims to identify clinical characteristics, response and clinical outcome of plasma cell dyscrasia (PCD) diagnosed in Zhongshan Hospital, Fudan University from May 2023. In its current version, the registry incorporates historical data (collected from 2007) and is prospectively collecting follow-up data and recording patient outcomes.",[54],"Multiple Myeloma and Other Plasma Cell Neoplasms","2024-12-30",{"date":57,"type":58},"2025-01-06","ACTUAL",{"date":60,"type":58},"2023-03-01",{"date":62,"type":50},"2028-12-31",{"name":5,"class":6},1]